OXFORD, U.K.--Computer-aided molecular design software vendor Oxford Molecular here announced March 31 that after five unprofitable years, in 1997 it achieved an overall pretax profit of £256,000 for the year. CEO Tony Marchington attributed increased sales to successful cheminformatics and bioinformatics businesses where Oxford's Omiga and RS3 products benefitted from strong customer demand. Oxford's June 1997 acquisition of two profitable firms, Genetics Computer Group and MLR Automation, further strengthened performance, Marchington said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.